



PATIENT	ORDERING PROVIDER	LABORATORY INFORMATION	
Sample	Kurt Odgers	Lab ID:	000000000000
DOB: 00/00/00	Mindovermetal	Collection Date:	00/00/00
	207 Regent Street	Test Date:	00/00/00
	London, W1B 3HH	Report Date:	00/00/00

COMT GG

The patient's genotype for COMT suggests rapid breakdown of catecholamines, most notably dopamine. A patient with this genotype may require higher doses of pain medication. A diet high in tyrosine may support continuous neurotransmitter production. Some research has found that the polyphenols EGCG and quercetin may inhibit the COMT enzyme.



PATIENT	ORDERING PROVIDER	LABORATORY INFORMATION
Sample	Kurt Odgers	Lab ID: 000000000000
DOB: 00/00/00	Mindovermetal	Collection Date: 00/00/00
	207 Regent Street	Test Date: 00/00/00
	London, W1B 3HH	Report Date: 00/00/00

ASSAY	RESULT	PHENOTYPE	ENZYME ACTIVITY
COMT	G/G	Normal	High

CLINICAL CONSEQUENCES

Homozygous Val/Val allele carriers exhibit higher COMT enzyme activity and thus have an increased capacity to degrade catecholamines; this can contribute to lower dopamine levels and a higher pain tolerance. Despite being more resilient to pain, Val/Val genotypes often require higher doses of morphine to obtain the same pain relief as other genotypes. Val/Val allele carriers may have an enhanced response to COMT inhibitors used in Parkinson's disease treatment and may have lower estradiol levels than those expressing other alleles.

COMT BACKGROUND INFORMATION

The COMT (catechol-O-methyltransferase) gene codes for the essential COMT enzyme that is involved in the inactivation of catecholamines such as dopamine, epinephrine, norepinephrine and catecholestrogens.¹⁻³ Scientific research has demonstrated that a common mutation in the COMT locus results in the replacement of the amino acid valine with methionine at position 158 in the enzyme. This causes a dramatic reduction in the enzyme's ability to metabolize these neurotransmitters and catecholestrogens.^{1,4} The enzyme is notably active in the prefrontal cortex (PFC), the area of the brain that gives rise to what we perceive as personality, emotions, behavior inhibition, abstract thinking, and short-term memory.⁵ Val/Val allele carriers have higher enzyme activity resulting in greater stress resiliency and lower dopamine levels, while Met/Met allele carriers have lower enzyme activity resulting in reduced stress resiliency and higher dopamine levels. Heterozygous Val/Met allele carriers exhibit an intermediate enzyme activity. Polymorphisms in the COMT gene have been implicated in association with various mental health disorders through the resulting changes in dopamine levels.^{1,2,5,6} Depending on the variant, associated disorders include drug abuse,⁷ alcohol abuse,⁸ severity of schizophrenic symptoms,^{9,10} obsessive compulsive disorder in men,¹¹ panic disorder,¹² post-traumatic stress disorder,¹³ and bipolar affective disorder.^{14,15} Having a particular polymorphism does not mean that someone will develop one or more of the associated disorders.



COMT

Genetic Analysis Report

Summary of Likely Patterns Associated with COMT Alleles

GENE ALLELE	ENZYME ACTIVITY	DOPAMINE LEVELS	PAIN RESPONSE	PAIN MED NEED	STRESS RESILIENCY	ESTRADIOL LEVELS
Val/Val	HIGH	LOWER	MORE TOLERANCE	POSSIBLE HIGHER DOSE	HIGHER	LIKELY LOWER
Val/Met	INTERMEDIATE	AVERAGE	AVERAGE	AVERAGE	AVERAGE	AVERAGE
Met/Met	LOW	HIGHER	MORE ACUTE	PROBABLY LOWER DOSE	REDUCED	LIKELY HIGHER

PAIN MANAGEMENT AND NEUROLOGICAL INFORMATION

COMT polymorphisms have been linked to pain sensitivity.^{16,17} It has been suggested that a reduction in dopamine inactivation, such as is seen with the Met/Met genotype, results in higher levels of dopamine, leading to chronic stimulation of the dopamine receptors. This overstimulation may result in less endogenous opioids being produced that help to provide pain relief and euphoria.¹⁷ Therefore, Met/Met allele carriers can perceive a higher level of pain, while Val/Val carriers have the greatest resistance to pain.^{16,17} Interestingly, studies have shown that Met/Met allele carriers require less morphine to achieve pain relief, possibly due to the increase in μ -opioid receptors seen with this genotype, while Val/Val allele carriers require the most medication for pain management.¹⁸ COMT also has been shown to have an effect on L-DOPA therapy in Parkinson's disease treatment.¹⁹ Commonly COMT inhibitors, such as entacapone, are utilized in Parkinson's treatment to augment and prolong L-DOPA treatment.²⁰ COMT polymorphisms affect the bioavailability of these medications, yielding a heightened effect of entacapone in the Val/Val allele carriers as compared to Met/Met allele carriers.

ESTRADIOL INFORMATION

COMT has also been demonstrated to play a role in estrogen metabolism through inactivation of the catecholestrogens.²¹ Catecholestrogens are formed during the metabolism of estrogens such as estradiol. Catecholesterol inactivation decreases the cancer-causing potential of these metabolites, while simultaneously increasing the amount of 2-methoxyestradiol, a metabolite that has been shown to inhibit the growth of breast cancer cells.^{4,22,23} Additionally, COMT polymorphisms have been shown to exert an effect on estradiol levels.²⁴ As Met/Met allele carriers exhibit a 2-3 fold decrease in their ability to degrade catecholestrogens, this results in higher estradiol levels than Val/Val allele carriers.^{4,25} Estradiol clearance is also diminished in both the Met/Met and Met/Val genotypes as opposed to Val/Val genotypes, however there is no significant difference in estrone levels.²⁴

**TREATMENT CONSIDERATIONS**

Homozygous Valine (Val/Val) allele carriers have lower dopamine levels. Increasing certain amino acids without proper balance of all neurotransmitters may result in increased cognitive symptoms.³²

- L-Tyrosine is an amino acid and a precursor to dopamine.³³ Dopamine precursors may be supportive of dopamine production; however, L-tyrosine's use in the treatment of individuals with the Val/Val genotype is theoretical as there have been no studies performed validating its effectiveness.
- COMT polymorphisms, specifically Val/Val homozygotes, may influence the plasma levels of homocysteine.⁴⁴ Individuals with high levels of homocysteine may benefit from supplementation with melatonin, which may lower homocysteine.⁴⁵
- Active B Complex vitamins are associated with the proper methylation of enzymes throughout the body and may lower homocysteine, while high levels of homocysteine are associated with cognitive impairment.²⁸⁻³¹
- Green tea may suppress COMT function, increase dopamine release, and suppress the production of reactive oxygen species, thereby inhibiting inflammatory responses.⁴⁶⁻⁴⁹ Additionally, intake of caffeine may support dopamine neurotransmission in conditions with dopamine deficiency.⁵⁰
- A small study in elderly adults found that increasing unsaturated fatty acids along with caloric restriction modulates cognition in homozygous (Val/Val) allele carriers.⁵¹
- A small study in elderly adults found that physical activity improves cognition in homozygous (Val/Val) allele carriers.⁵²

SCIENTIFIC REFERENCES

1. Lachman H et al. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. *Pharmacogenetics* 1996; 6:243-250.
2. Weinshilboum R et al. Methylation Pharmacogenetics: Catechol-O methyltransferase, Thiopurine Methyltransferase, and Histamine N-Methyltransferase. *Annu. Rev. Pharmacol. Toxicol.* 1999; 39:19-52.
3. Mannisto P and S Kaakkola. Catechol-O-methyltransferase (COMT): Biochemistry, Molecular Biology, Pharmacology, and Clinical Efficacy of the New Selective COMT Inhibitors. *Pharm Rev.* 1999; 51(4):594-622.
4. Dawling S et al. Catechol-O-Methyltransferase (COMT)-mediated Metabolism of Catechol Estrogens: Comparison of Wild-Type and Variant COMT Isoforms. *Cancer Res.* 2001; 61:6716-6722.
5. Mier D et al. Neural substrates of pleiotropic action of genetic variation in COMT: a meta-analysis. *Molecular Psychiatry.* 2010; 15:918-927.
6. Goldman D et al. The Genetics of Addictions: Uncovering the Genes. *Nat Rev Genet.* 2005; 6(7):521-532.
7. Yuferov V et al. Search for Genetic Markers and Functional Variants Involved in the Development of Opiate and Cocaine Addiction, and Treatment. *Ann N Y Acad Sci.* 2010; 1187:184-207.
8. Schellekens AF et al. COMT Val158Met modulates the effect of childhood adverse experiences on the risk of alcohol dependence. *Addict Biol.* 2013; 18(2):344-356.
9. Bhakta SG et al. The COMT Met158 allele and violence in schizophrenia: a meta-analysis. *Schizophr Res.* 2012; 140(1-3):192-197.
10. Godar SC and M Bortolato. Gene-sex interactions in schizophrenia: focus on dopamine neurotransmission. *Front Behav Neurosci.* 2014; 8:71.
11. Pooley EC et al. The met158 allele of catechol-o-methyltransferase (COMT) is associated with obsessive-compulsive disorder in men: case-control study and meta-analysis. *Mol Psych.* 2007; 12:556-551.
12. Konishi Y et al. Genexgenxgender interaction of BDNF and COMT genotypes associated with panic disorder. *Prog Neuropsychopharmacol Biol Psychiatry.* 2014; 51:119-125.
13. Kolassa IT et al. The risk of posttraumatic stress disorder after trauma depends on traumatic load and the catechol-o-methyltransferase Val(158)Met polymorphism. *Biol Psychiatry.* 2010; 67(4):304-308.
14. Lee SY et al. COMT and BDNF interacted in bipolar II disorder not comorbid with anxiety disorder. *Behav Brain Res.* 2013; 237:243-248.



15. Zhang Z. The Val/Met functional polymorphism in COMT confers susceptibility to bipolar disorder: evidence from an association study and a meta-analysis. *J Neural Transm.* 2009; 116(10):1193-200.
16. Janicki PK. Pharmacogenetics of Pain Management. *Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches.* Edited by TR Deers. American Academy of Pain Medicine. 2013.
17. Zubieta JK et al. COMT val158met Genotype Affects mu-opioid Neurotransmitter Responses to a Pain Stressor. *Science.* 2003; 299(5610):1240-1243.
18. Klepstad P et al. Genetic variability and clinical efficacy of morphine. *Acta Anaesthesiol Scand.* 2005; 49:902-908.
19. Mannisto PT and S Kaakkola. Catechol-O-methyltransferase (COMT): Biochemistry, Molecular Biology, Pharmacology, and Clinical Efficacy of the New Selective COMT Inhibitors. *Pharm Rev.* 1999; 51(4):594-622.
20. Corvol JC et al. The OCMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. *Ann Neurol.* 2011; 69(1):111-118.
21. Ball P and R Knuppen. Catechol-oestrogens (2-and 4-hydroxyoestrogens): chemistry, biogenesis, metabolism, occurrence and physiological significance. *Acta Endocrinol. Suppl. (Copenh).* 1980; 232:1-127.
22. Lakhani NJ et al. 2-Methoxyestradiol, a Promising Anticancer Agent. *Pharmacotherapy.* 2003; 23:165-172.
23. Lavigne JA et al. The Effects of Catechol-O-Methyltransferase Inhibition on Estrogen Metabolite and Oxidative DNBA Damage Levels in Estradiol-treated MCF-7 Cells. *Cancer Research.* 2001; 61:7488-7494.
24. Worda C et al. Influence of the catechol-O-methyltransferase (COMT) codon 158 polymorphism on estrogen levels in women. *Human Reproduction.* 2003; 18(2):262-266.
25. Eriksson AL et al. The COMT val158met polymorphism Is Associated with Early Pubertal Development, Height and Cortical Bone Mass in Girls. *Pediatr Res.* 2005; 58(1):71-77.
26. Sarris J et al. S-adenosyl methionine (SAmE) versus escitalopram and placebo in major depression RCT: Efficacy and effects of histamine and carnitine as moderators of response. *J Affect Disord.* 2014; 164:76-81.
27. Fava M et al. Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. *Psychiatry Res.* 1995; 56(3):295-297.
28. Haan M et al. Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: Results from the Sacramento Area Latino Study on Aging. *Am J Clin Nutr.* 2007; 85(2):511-517.
29. Smith A et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: A randomized controlled trial. *PLoS One.* 2010; 5(9):1-10.
30. Mitchell E et al. B vitamin polymorphisms and behavior: Evidence of associations with neurodevelopment, depression, schizophrenia, bipolar disorder and cognitive decline. *Neurosci Biobehav Rev.* 2014; 47:307-320.
31. Kennedy D et al. Effects of high-dose B vitamin complex with vitamin C and minerals on subjective mood and performance in healthy males. *Psychopharmacology (Berl).* 2010; 211(1):55-68.
32. Masurier M et al. Effect of Acute Tyrosine Depletion in Using a Branched Chain Amino-Acid Mixture on Dopamine Neurotransmission in the Rat Brain. *Neuropsychopharmacology.* 2006; 31(2):310-317.
33. Fernstrom HD and MH Fernstrom. Tyrosine, Phenylalanine, and Catecholamine Synthesis and Function in the Brain. *J. Nutr.* 2007; 137(6):1539S-1547S.
34. Reus G et al. Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies. *J Psychiatr Res.* 2015; 68:316-328.
35. Jangid P et al. Comparative study of efficacy of L-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode. *Asian J Psychiatr.* 2013; 6(1):29-34.
36. Lowe S et al. L-5-Hydroxytryptophan augments the neuroendocrine response to a SSRI. *Psychoneuroendocrinology.* 2006; 31(4):473-484.
37. Lardner A et al. Neurobiological effects of the green tea constituent theanine and its potential role in the treatment of psychiatric and neurodegenerative disorders. *Nutritional Neuroscience.* 2014; 17(4):145-155.
38. Mu W et al. An overview of biological production of L-theanine. *Biotechnol Adv.* 2015; 33(3-4):335-342.
39. Kakuda T. Neuroprotective effects of theanine and its preventive effects on cognitive dysfunction. *Pharmacol Res.* 2011; 64(2):162-168.
40. Tian X et al. Protective effect of L-theanine on chronic restraint stress-induced cognitive impairments in mice. *Brain Res.* 2013; 1503:24-32.
41. Martínez-Banaclocha M et al. N-acetyl-cysteine in the treatment of Parkinson's disease. What are we waiting for? *Med Hypotheses.* 2012; 79(1):8-12.
42. Dean, O et al. N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: Relevance to schizophrenia and bipolar disorder. *Neurosci Lett.* 2011; 499(3):149-153.
43. Botsakis K et al. 17β-Estradiol/N-acetylcysteine interaction enhances the neuroprotective effect on dopaminergic neurons in the weaver model of dopamine deficiency. *Neuroscience.* 2016; 320:221-229.
44. Tunbridge E et al. Polymorphisms in the catechol-O-methyltransferase (COMT) gene influence plasma total homocysteine levels. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics* 147.6 (2008):996-999.
45. Paul R and A. Borah. The potential physiological crosstalk and interrelationship between two sovereign endogenous amines, melatonin and homocysteine. *Life Sci.* 2015; 139:97-107.
46. Hursel R et al. The Role of Catechol-o-Methyl Transferase Val (108/158) MET Polymorphism (rs4680) in the effect of Green Tea on Resting Energy Expenditure and Fat Oxidation: A Pilot Study. 2014; 9(9): e106220.



47. Lorenz M et al. The activity of catechol-O-methyltransferase (COMT) is not impaired by high doses of epigallocatechin-3-gallate (EGCG) in vivo. *Eur J Pharmacol.* 2014; 740: 645-651.
48. Kang K et al. Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration. *Brain Res.* 2013; 1497:1-14.
49. Kang K et al. Dual beneficial effects of (-)-epigallocatechin-3-gallate on levodopa methylation and hippocampal neurodegeneration: In vitro and in vivo studies. *PLoS One.* 2010; 5(8): e11951.
50. Xie X et al. Adenosine and dopamine receptor interactions in striatum and caffeine-induced behavioral activation. *Comp Med.* 2007; 57(6):538-545.
51. Witte A et al. COMT Val158Met polymorphism modulates cognitive effects of dietary intervention. *Front Aging Neurosci.* 2010; 2:146.
52. Voelcker-Rehage C et al. COMT gene polymorphisms, cognitive performance, and physical fitness in older adults. *Psychol Sport Exerc.* 2015; 20:20-28.
53. McCann S. et al. Changes in 2-hydroxyestrone and 16 α -hydroxyestrone metabolism with flaxseed consumption: Modification by COMT and CYP1B1 genotype. *Cancer Epidemiology Biomarkers & Prevention.* 2007; 16(2):256-262.
54. Rižner TL. Estrogen biosynthesis, phase I and phase II metabolism, and action in endometrial cancer. *Mol Cell Endocrinol.* 2013; 381(1-2):124-139.
55. Papaleo F et al. Sex-dichotomous effects of functional COMT genetic variations on cognitive functions disappear after menopause in both health and schizophrenia. *Eur Neuropsychopharmacol.* 2015; 25 (12): 2349-2363.
56. Almey A et al. Estrogen receptors in the central nervous system and their implication for dopamine-dependent cognition in females. *Horm Behav.* 2015; 74:125-138.
57. Jeffery DR and JA Roth. Kinetic reaction mechanism for magnesium binding to membrane-bound and soluble catechol O-methyltransferase. *Biochem.* 1987; 26(10):2955-2958.
58. Sowa-Kucma M et al. Zinc, magnesium and NMDA receptor alterations in the hippocampus of suicide victims. *J Affect Disord.* 2013; 151(3):924-931.
59. Basheer, MP et al. A study of serum magnesium, calcium and phosphorus level, and cognition in the elderly population of South India. *Alexandria J Med.* 2016; 52 (4): 303-308.
60. Yary T et al. Dietary magnesium intake and the incidence of depression: A 20 year follow-up study. *J Affect Disord.* 2016; 193:94-98.

Reported and Reviewed By:

Zahra Mehdizadeh Kashi, Ph.D., HCLD
CEO and Laboratory Director

Methodology: All SNP genotyping is performed by Real-Time PCR using either pre-designed, or custom, Applied Biosystems™ TaqMan SNP Genotyping assays and TaqMan Genotyper Analysis Software v1.4.0 to detect specific polymorphisms within the targeted gene locus and assign genotypes at an analytical sensitivity and specificity >99%.

NOTICE: This information does not take into consideration patient health history, interaction with other medications or supplements, and/or allergies. It is the responsibility of the physician to determine appropriate medication

dosing choices, or clinical actions, based on all clinical data. Therefore, we encourage you to consider further independent testing, as well as checking with your physician and/or also seeking professional genetic counseling.

This test detects only specific targeted genetic variations and there is a possibility that other genetic variants not detected by this test may be present. This test will not detect all the known variants for a target gene that result in an altered or inactive tested gene. This test does not account for all individual genetic, epigenetic or structural variations in the individual tested. Even with gene sequencing, variant detection rate is not 100% since sequencing of the coding regions will typically not reveal or detect pathogenic intronic variants, large exonic deletions/duplications, or whole gene deletions/duplications. A negative test result therefore, does not completely rule out the possibility that the patient is a carrier. Absence of a detectable gene mutation does not rule out the possibility that a patient has a different phenotype due to the presence of an undetected polymorphism or due to other factors such as drug-drug interactions, comorbidities or lifestyle habits.

The DNA variants tested for in this report have been scientifically determined to be possible risk factors for the reported condition. Our laboratory always seeks to follow ACMG guidelines and presents findings within our reports as they become available. The content of this report is provided for informational purposes only, not as a diagnostic tool. The report does not supersede the judgment of a qualified medical provider. This test is not a substitute for a comprehensive consideration of all factors that influence the maintenance of a healthy body. Genetic risk factors are not guarantees that you will develop a condition, and in many cases, the presence of a particular DNA variant may only play a minor role in your risk for disease, compared with environmental and lifestyle factors. Many clinical conditions/diseases are extremely heterogeneous at the molecular level and variant allele prevalence can vary based on ethnicity or geography or gender. In general, without a complete patient profile of all genetic, environmental and lifestyle information, residual risk, recurrent risk, penetrance and prevalence of a single genetic marker's contribution is not within the scope of the laboratory to determine. This test is not FDA approved. The test's performance characteristics have been established and maintained by Kashi Clinical Laboratories under CLIA and CAP.